Galera raises $37 million to develop new anti-chemotherapy side effects

Release date: 2015-10-16

As we all know, in recent years, many new therapies have emerged in the field of cancer therapy development, such as CAR-T therapy, checkpoint therapy and so on. But today, radiotherapy and chemotherapy is still the absolute main force to fight the tumor front. However, because radiotherapy and chemotherapy are not targeted, patients often kill one thousand after receiving treatment, and self-destruction is 800. Therefore, how to reduce the side effects caused by radiotherapy and chemotherapy has become an important issue to improve the treatment of cancer.

Recently, Galera Pharmaceuticals, Inc. of Pennsylvania, USA, completed a Series B round of financing worth $37 million. The company will use the funds to develop a new drug, GC4419, for the treatment of oral mucositis caused by radiotherapy in patients with head and neck cancer. According to statistics, 80% of patients with head and neck cancer will have serious side effects of oral mucositis after receiving radiotherapy. This side effect may cause a series of problems including bacterial infections, and even hinder further treatment of the patient in severe cases.

GC4419 is a dismutase mimetic that is used primarily to regulate the oxidative metabolic pathway and accelerate the production of hydrogen peroxide by targeting the superoxide pathway, thereby reducing the damage of normal cells by radiotherapy. This drug is considered to be widely used in the fields of tumor inflammation, fibrosis and mitochondrial diseases. At present, GC4419 has completed a clinical phase II study of proof of concept. Next, the company plans to carry out a larger clinical phase II study to accelerate the development of this drug. It is understood that there are currently no drugs listed on the market for oral mucositis in patients with head and neck cancer.

The work of Galera also attracted the attention of some pharmaceutical giants. In this round of financing, Novo Ventures under Novo Nordisk and Novartis Venture Fund under Novartis were involved. New Enterprise Associates, which led Galera's Series A financing in 2012, also participated.

Source: Bio Valley

Medical Disinfection Products

Blood Pressure Monitor,Medical Digital Blood Pressure Monitor,Medical Alcohol Swabs,Disposable Alcohol Prep Swab,Antiseption Clean Wipe

Surgimed Medical Supplies Co.,Ltd , https://www.surgimedcn.com